(Q79894989)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

main subject

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Valter Gattei

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Giovanni Del Poeta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

Maria Ilaria Del Principe

26 December 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

M Christina Cox

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sergio Amadori

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Adriano Venditti

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

8

M Irno Consalvo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

L Maurillo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

P Panetta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

C Mazzone

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

B Neri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

L Ottaviani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

D Fraboni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

A Tamburini

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

F Lo-Coco

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

13 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

1783-1789

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16838027%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404313

26 December 2019

exact match

0 references

cites work

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Determination of minimal residual disease in leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404313

7 January 2021